Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies-Reference-Cited by-同舟云学术

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

Published:2012-05-29 Issue:2 Volume:134 Page:583-593
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Chen Albert C.,Migliaccio Ilenia,Rimawi Mothaffar,Lopez-Tarruella Sara,Creighton Chad J.,Massarweh Suleiman,Huang Catherine,Wang Yen-Chao,Batra Surinder K.,Gutierrez M. Carolina,Osborne C. Kent,Schiff Rachel

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-012-2082-9.pdf

Reference55 articles.

1. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R (2007) Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99(9):694–705. doi: 10.1093/jnci/djk151

2. Arpino G, Wiechmann L, Osborne CK, Schiff R (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29(2):217–233. doi: 10.1210/er.2006-0045

3. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68(3):826–833. doi: 10.1158/0008-5472.CAN-07-2707

4. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI (2006) Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96(2):131–146. doi: 10.1007/s10549-005-9070-2

5. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3):1032–1044

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care;Cancers;2024-04-19

2. Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer;Biomedicine & Pharmacotherapy;2023-06

3. Emerging Targeted Therapies for HER2-Positive Breast Cancer;Cancers;2023-03-26

4. The role of membrane mucin MUC4 in breast cancer metastasis;Endocrine-Related Cancer;2022-01-01

5. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers;Molecular Biology Reports;2021-11-05